Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Product revenue $ 239 $ 66 $ 441 $ 478
Costs of revenue 190 53 324 382
Gross profit 49 13 117 96
Operating expenses:        
Research and development 1,603 1,432 4,402 3,494
General and administrative 933 827 2,791 2,418
Sales and marketing 338 182 953 450
Total operating expenses 2,874 2,441 8,146 6,362
Loss from operations (2,825) (2,428) (8,029) (6,266)
Other income (expenses):        
Interest expense (1) (1) (2) (2)
Interest income 3 78 99 267
Change in fair value of derivative liabilities 481 (287) 225 1,750
Offering costs (1,246)
Forgiveness of PPP loan 391
Other income (expense), net (1) 200 141 200
Total other income (expense), net 482 (10) 854 969
Net loss before income taxes (2,343) (2,438) (7,175) (5,297)
Provision for income taxes
Net loss (2,343) (2,438) (7,175) (5,297)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock (74) (9,565)
Net loss attributable to common stockholders $ (2,343) $ (2,512) $ (7,175) $ (14,862)
Net loss per share – basic and diluted        
Basic – net loss $ (0.09) $ (0.11) $ (0.29) $ (0.39)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock (0.70)
Basic – attributable to common stockholders (0.09) (0.11) (0.29) (1.09)
Diluted –net loss (0.11) (0.11) (0.29) (0.49)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock (0.63)
Diluted – attributable to common stockholders $ (0.11) $ (0.11) $ (0.29) $ (1.12)
Weighted average common shares outstanding:        
Basic 24,703,156 22,774,263 24,686,533 13,671,866
Diluted 25,069,343 22,774,263 25,097,138 15,094,276